Torray Fund BMY trades
Robert Torray
Torray Fund Bristol-Myers Squibb Company stake
total: 71
Trades details
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 2
- Held since:
- 2020 Q1
- Held for:
- 13 quarters
- Latest activity:
- 2023 Q2
According to 2026 Q2 report, Torray Fund doesn't hold any Bristol-Myers Squibb Company (BMY) shares. To date, the estimated cost basis is nearly $57.46 for "buy" trades and estimated average "sell" price is $70.59. Torray Fund first purchased BMY in 2020 Q1, initially acquiring 163,400 shares. Since the initial investment in Bristol-Myers Squibb Company (BMY), Torray Fund has made 4 more transactions.
When did Torray Fund sell Bristol-Myers Squibb Company (BMY)?
Torray Fund sold off the entire Bristol-Myers Squibb Company (BMY) position in 2023 Q2.
When did Torray Fund buy Bristol-Myers Squibb Company (BMY)?
Torray Fund first invested in Bristol-Myers Squibb Company (BMY) in 2020 Q1 at the reported quarter-end price of $55.74 per share.
What's the cost basis of Torray Fund's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $57.46 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $57.46
- Weighted AVG sell price:
- $70.58
Torray Fund's historical trades in Bristol-Myers Squibb Company
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$69.31
|
|
-100% (-157,493)
|
-3.53%
|
|
2022 Q3
|
3.93%
|
157,493
|
$71.09
|
$11,196,177
|
-14.33% (-26,346)
|
-0.62%
|
|
2022 Q2
|
4.67%
|
183,839
|
$77.00
|
$14,155,603
|
-13.72% (-29,231)
|
-0.63%
|
|
2021 Q1
|
3.47%
|
213,070
|
$63.13
|
$13,451,109
|
+30.40% (+49,670)
|
+0.81%
|
|
2020 Q1
|
3.08%
|
$55.74
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.